#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote […]

The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million Americans living with a history of cancer last year, […]

Kognitic is excited to be heading to #JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website to see how […]

Thank you Healthcare Tech Outlook for featuring Kognitic in the Top Ten Oncology Companies of 2019. We are thrilled to be listed alongside other innovative companies […]

A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been […]

We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitable access to clinical trials for all […]

In honor of Lung Cancer Awareness Day (August 1st), we would like to call attention to assets currently in phase III for small cell lung cancer! […]

Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached article). So which modalities is […]

Interesting article about BMS expanding Opdivo’s colorectal cancer indication. Which companies could be impacted by this expansion? Kognitic’s platform can show you which companies have new […]